Zosano Pharma Announces Keynote Speech at the Pharmaceutics & Advanced Drug Delivery Systems Conference
03 7월 2019 - 9:30PM
Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage
biopharmaceutical company, today announced that Hayley Lewis,
senior vice president of operations at Zosano Pharma, will be
presenting a keynote speech entitled, “A Novel Intracutaneous
Microneedle Delivery System for the Acute Treatment of Migraine” at
the Pharmaceutics & Advanced Drug Delivery Systems Conference
in Paris on July 5, 2019 at 09:15 am CET.
Ms. Lewis’ presentation will review Zosano’s novel
and proprietary technology platform, the chemistry, manufacturing,
and controls of the company’s lead asset, Qtrypta. In addition, Ms.
Lewis will cover highlights of the clinical program.
“I am delighted to be giving the keynote at this
year’s Pharmaceutics & Advanced Drug Delivery Conference. As we
continue to build the NDA for Qtrypta, we are excited about
bringing this novel technology to the FDA for their review,” said
Hayley Lewis, senior vice president of operations at Zosano.
“Qtrypta, if approved, will be the first microneedle system on the
market in the US, and is paving the way for this mode of delivery.
The conference is great place to showcase our development, as well
as the unique features and benefits of this technology.”
The Pharmaceutics & Advanced Drug Delivery
Systems Conference is a forum for researchers, scientists,
pharmacists, pharmacologists, academicians, and other healthcare
professionals to exchange knowledge on cutting-edge technologies,
research and development, new therapeutics, and challenges in the
field of pharmaceutics and drug delivery.
About Zosano PharmaZosano Pharma
Corporation is a clinical stage biopharmaceutical company focused
on developing products where rapid administration of established
molecules with known safety and efficacy profiles provides an
increased benefit to patients, for markets where patients remain
underserved by existing therapies. The company’s Adhesive
Dermally-Applied Microarray (ADAM) technology consists of titanium
microneedles coated with drug that can enable rapid systemic
administration of therapeutics to patients. Zosano’s lead product
candidate is Qtrypta™ (M207), which is a proprietary
formulation of zolmitriptan delivered via ADAM technology, as an
acute treatment for migraine. The company is preparing to submit a
New Drug Application (NDA) to the Food and Drug Administration for
Qtrypta. The Company anticipates that many of its current and
future development programs may enable the Company to utilize a
regulatory pathway that would streamline clinical development and
accelerate the path towards commercialization. Learn more at
www.zosanopharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements regarding the
expected NDA filing for Qtrypta (M207) and other future events and
expectations. Readers are urged to consider statements that include
the words "may," "will," "would," "could," "should," "might,"
"believes," "estimates," "projects," "potential," "expects,"
"plans," "anticipates," "intends," "continues," "forecast,"
"designed," "goal," "unaudited," "approximately" or the negative of
those words or other comparable words to be uncertain and
forward-looking. These statements are subject to risks and
uncertainties that are difficult to predict, and actual outcomes
may differ materially. These include risks and uncertainties,
without limitation, associated with the process of discovering,
developing and commercializing products that are safe and effective
for use as human therapeutics, risks inherent in the effort to
build a business around such products and other risks and
uncertainties described under the heading "Risk Factors" in the
Company's most recent quarterly report on Form 10-Q. Although
Zosano believes that the expectations reflected in these
forward-looking statements are reasonable, we cannot in any way
guarantee that the future results, level of activity, performance
or events and circumstances reflected in forward-looking statements
will be achieved or occur. All forward-looking statements are based
on information currently available to Zosano and Zosano assumes no
obligation to update any such forward-looking statements.
Zosano Contact:Greg KitchenerChief
Financial Officer510-745-1200
PR Contacts:Sylvia Wheeler or
Alexandra Santosswheeler@wheelhouselsa.com or
asantos@wheelhouselsa.com
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Zosano Pharma (NASDAQ:ZSAN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024